Last reviewed · How we verify
LD+I+TRB
LD+I+TRB is a combination therapy that likely combines a diuretic (LD), an ACE inhibitor or ARB (I), and a beta-blocker (TRB) to reduce cardiac workload and improve heart function.
LD+I+TRB is a combination therapy that likely combines a diuretic (LD), an ACE inhibitor or ARB (I), and a beta-blocker (TRB) to reduce cardiac workload and improve heart function. Used for Heart failure (likely systolic heart failure with reduced ejection fraction), Hypertension.
At a glance
| Generic name | LD+I+TRB |
|---|---|
| Also known as | SD+I+TRB, LD+TRB |
| Sponsor | Tabba Heart Institute |
| Drug class | Fixed-dose combination antihypertensive/heart failure therapy |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This triple-drug combination targets multiple pathways in heart failure management: the diuretic reduces fluid overload and preload, the ACE inhibitor/ARB blocks the renin-angiotensin-aldosterone system to reduce afterload and prevent remodeling, and the beta-blocker decreases heart rate and contractility to reduce myocardial oxygen demand. Together, these agents work synergistically to improve cardiac hemodynamics and reduce mortality in heart failure patients.
Approved indications
- Heart failure (likely systolic heart failure with reduced ejection fraction)
- Hypertension
Common side effects
- Hypotension
- Hyperkalemia
- Renal impairment
- Bradycardia
- Fatigue
- Dizziness
Key clinical trials
- Low Dose Heparin Factorial Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |